Target intelligence / Profile preview

NKG2D ligand (NKG2D-L)

Target
NKG2D-L
Molecular classification
Receptor ligand, Immune recognition molecule, MHC class I-like molecule, Tumor-associated antigen
01

Overview

NKG2D ligands are a family of stress-inducible molecules (including MICA, MICB, and ULBPs) overexpressed in various cancers and other pathological states. These ligands bind to the activating NKG2D receptor on natural killer (NK) cells, triggering NK-mediated lysis of the transformed or infected cells. Their expression facilitates immune recognition but is subject to tumor-driven evasion by ligand shedding, downregulation, or immune checkpoint inhibition. Therapeutic exploitation includes antibody-based strategies, CAR cell engineering, and immune checkpoint blockade, although clinical translation faces challenges in selectivity and tolerance.

Other names
NKG2D ligandMICAMICBUL16-binding protein (ULBP)Stress-induced ligand
02

Mechanism of action

Antibody-dependent cellular cytotoxicity (ADCC); Direct receptor-ligand induced cytotoxicity (NKG2D-mediated); Enhancement of NK cell activation; Modulation of immune checkpoints

03

Biological functions

Immune responseTumor cell recognitionActivation of NK cell cytotoxicitySignal transductionRegulation of cell killing
04

Disease associations

CancerViral infectionInflammationImmune evasionSenescence
05

Safety considerations

Tumor escape mechanisms via shedding or downregulation of NKG2D ligandsPotential for off-tumor cytotoxicity and tissue damageInduced immune tolerance or exhaustion with chronic ligand exposure
06

Interacting drugs

Monoclonal antibodies targeting NKG2D or its ligands

2 more in the full profile.

07

Biomarkers

Surface expression of MICA, MICB, and ULBPs on tumor cellsShedding levels of soluble NKG2D ligandsExpression of NKG2D on NK cells

Beyond the preview

Go deeper on NKG2D ligand (NKG2D-L).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKG2D ligand (NKG2D-L).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call